Prediction of intestinal absorption and brain penetration of drugs by Virághné Hellinger Éva
Prediction of intestinal absorption and brain 
penetration of drugs 
 
 
PhD thesis 
 
 
Éva Hellinger Pharm.D. 
 
Semmelweis University 
Doctoral School of Pharmaceutical Sciences 
  
 
 
Supervisor:      Dr. Károly Tihanyi Ph.D 
Consultant:      Dr. Monika Vastag Ph.D 
 
Official reviewers:    Prof. Dr. Kornélia Tekes Ph.D. 
      Dr. Katalin Jemnitz Ph.D. 
 
Head of the Final Exam Committee:  Prof. Dr. Tamás Török D.Sc.  
 
Members of the Final Exam Committee:   
Prof. Dr. Imre Klebovich D.Sc.  
Dr. István Krizbai Ph.D. 
 
Budapest, 2012 
 
 2 
1. INTRODUCTION 
 
P-glycoprotein (P-gp, MDR1) is a limiting efflux transporter involved in drug 
penetration. The P-gp is located on the apical side of polarized cell membranes of both 
the intestinal mucosa and blood-brain barrier (BBB). P-gp mediated efflux has been 
recognized as a serious limiting factor in brain entry, and it also influences the intestinal 
absorption of low permeability or dissolution limited P-gp substrate drugs. 
Consequently, these drugs have reduced or variable plasma levels and non-linear 
pharmacokinetics. 
The permeability of new chemical entities (NCE) is routinely screened in 
preclinical drug research. The comparison of various models for the prediction of 
human absorption as well as brain penetration of NCEs is a prerequisite of successful 
compound selection.  
In the pharmaceutical research Caco-2 is the preferred cell-based model for 
human drug absorption. However, there is a variable and low expression of P-gp in 
Caco-2 cultures, which seems to limit its use for screening of P-gp substrates or 
studying P-gp related interactions. Improved P-gp expression and functionality of Caco-
2 cells was set as an objective by several laboratories.  
In vitro models of brain penetration that display adequate passive permeability 
and efflux transporter functionality with good human predictability simultaneously are 
also much-needed tools in early drug research. The epithelial cell line based surrogate 
models of BBB penetration can be fast, cheap and easy to handle alternatives of primary 
brain endothelial-based models in early BBB penetration screening. Highly comparable 
in vitro – in vivo BBB permeability correlations were achievable with epithelial cell 
MDCK-MDR1 model. Native Caco-2 is also increasingly investigated in comparative 
studies for BBB permeability prediction too. 
For the time being no standard model has yet emerged for the prediction of BBB 
penetration; there is certainly a lack of comparative data between brain capillary 
endothelial cell-based models and epithelial-based surrogate models. 
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2. AIMS 
 
Our aims were: 
 
-To establish a culture with higher and steady P-gp functionality by the 
modification of Caco-2 cells. 
 
-To examine the effect of sustained vinblastine treatment of Caco-2 cells on the 
expression and functionality of P-gp (VB-Caco-2). 
 
-To characterize and validate VB-Caco-2 model for long term use for drug 
penetration screening, P-gp substrate and inhibitor identification in bidirectional 
transport assay, and in Calcein-AM assay. 
 
-To elucidate the mechanism of vinblastine effect on P-gp level. 
 
-To compare the primary brain capillary endothelial BBB model (EPA) and the 
epithelial cell-based (Caco-2, VB-Caco-2, MDCK-MDR1) models as possible 
surrogate BBB models, with special respect to the critical BBB features 
(presence of discriminative paracellular pathway, BBB-like selective 
transcellular penetration and expression and function of P-gp). 
 
-To test these models for prediction of in vivo BBB penetration. 
 
-To compare a large set of in vitro permeability data obtained in parallel with the 
well accepted surrogate BBB model MDCK-MDR1 and the high P-gp 
expressing VB-Caco-2 models of drug penetration. 
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3. METHODS 
 
Cell cultures 
 
Caco-2 cells: Caco-2 cells (HTB-37) at passage 17 were obtained from the 
ATCC (American Type Culture Collection, Rockville, MD, USA). The cells were 
routinely cultured and differentiated in standard tissue culture medium consisting of 
Minimal Essential Medium supplemented with 20% foetal bovine serum, penicillin (100 
unit/ml), streptomycin (0.1 mg/ml) and sodium pyruvate (1mM).  
 
VB-Caco-2 cells: VB-Caco-2 cultures were created from Caco-2 cultures by 
growing cells in 10 nM vinblastine supplemented standard tissue culture medium during 
subcultivation in flasks and differentiation in Transwell inserts. 
For transport assay, Western blot, RT-PCR, CYP activity measurements and 
electron microscopy the cells were seeded at 5 x 105 cells per 1.12 cm2 density on EC 
Matrix (ATCC, USA) covered Costar Transwell inserts (polycarbonate, 12 mm 
diameter, 0.4 µm pore size; Corning Incorporated, Corning, NY, USA) and used for the 
assays on days 19-21. VB-Caco-2 cultures were studied between passages 48 to 201 and 
Caco-2 between 35 to 93. 
 
MDCK cells: Parent and MDR1 transfected Madin-Darby canine kidney 
epithelial cells were obtained from the Netherlands Cancer Institute (Amsterdam, The 
Netherlands). The cells were cultured in a tissue culture medium consisting of 4.5 g/l 
glucose containing Dulbecco’s Modified Eagle’s Medium supplemented with 10% 
foetal bovine serum, penicillin (50 units) and streptomycin (0.05 mg/ml) all from Gibco. 
The cells were used for up to 20-30 passages as long as their original properties were 
preserved. For transport assay and Western blot the cells were seeded at 5 x 105 cells 
per 1.12 cm2 density on Costar Transwell inserts and used for the assays on days 3-4.  
 
Rat BBB model: Rat brain capillary endothelial cells were used in a triple co-
culture model. Primary cultures of brain endothelial cells, astrocytes and pericytes, and 
construction of the in vitro BBB model were prepared by Nakagawa et al. (Nagasaki 
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University, Japan) and Deli et al. (Biological Research Centre of the Hungarian 
Academy of Sciences, Szeged, Hungary). Cells were seeded on collagen and fibronectin 
coated Costar Transwell polycarbonate membranes (12 mm diameter, 3 µm pore size; 
Corning Incorporated, Corning, NY, USA) for the permeability measurements. 
 
Cell morphology 
 
The morphology of native cells in flasks and toluidine blue stained cells on 
Transwell inserts was monitored using inverse phase contrast microscopy. Micrographs 
were taken from cells cultured in T75 flasks. Cells grown on the membrane of the 
culture inserts were fixed and examined using a Hitachi 7100 transmission electron 
microscope (Hitachi Ltd., Tokyo, Japan). 
 
Immunostaining 
 
Cells cultured on polyester membrane Transwell-Clear inserts were stained for 
the junctional proteins -catenin, ZO-1 and claudin-1, -4 and -5, and monolayers grown 
on glass coverslips were stained for P-glycoprotein, then were fixed. Cells were blocked 
with 3% BSA and incubated with primary antibodies (anti--catenin, ZO-1, claudin-1, -
4, -5 in 1:200 and P-glycoprotein in 1:100 for 1 h 30 min). Incubation with secondary 
antibody Cy3-labeled anti-rabbit IgG (Sigma–Aldrich) or anti-mouse-IgG-Alexa 488 
(Invitrogen), dilution 1: 500, lasted for 1 h.  
 
Real-time PCR 
 
RNA was extracted from cells cultured in flasks and Transwell inserts using 
RNeasy Mini Kit (Qiagen, Hilden, Germany), following the manufacturer's protocol. 
The reverse transcription was carried out in a Gene ATAQ Controller thermal cycler 
(Pharmacia LKB, Uppsala, Sweden). PE Applied Biosystems designed real-time PCR 
primers for MDR1 and the housekeeping 18S ribosomal RNA and TaqMan universal 
PCR master mix reagent were used to perform the PCR in 96-well optical reaction 
plates in an ABI Prism 7000 Sequence Detection System (PE Applied Biosystems).  
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Western blot 
 
For Western blotting, 25 µg protein samples of cell lysates were loaded on 7.5% 
Tris-HCl Ready Gels (BioRad Laboratories, Hercules, CA, USA) and blotted onto 
polyvinylidene difluoride membrane (BioRad Laboratories). Blots were probed with 
primary mouse anti-P-glycoprotein monoclonal antibody (Clone C219, Calbiochem, La 
Jolla, CA, USA in a dilution of 1:100 or 1:20), or for loading control with primary 
rabbit anti-actin polyclonal antibody (1:200, Sigma-Aldrich). Then, secondary 
antibodies (goat anti-mouse HRP-conjugated IgG; 1:10 000; Calbiochem, for anti-P-gp; 
or goat anti-rabbit HRP-conjugated IgG antibody 1:3000, Bio-Rad, for anti-actin) were 
added for 1 hour at room temperature. Chemoluminescence method (SuperSignal West 
Pico Chemiluminescent Substrate, Thermo scientific Rockford, IL, USA) was applied 
for detection of P-gp. For loading control, 3,3'-diaminobenzidine (Sigma-Aldrich) was 
used. 
 
Bidirectional transport assay 
 
The permeability of the test compounds was measured using bidirectional 
transport assay, in the apical-to-basolateral (A-B) and basolateral-to-apical (B-A) 
directions at 37 °C with moderate shaking (120 rpm). For highly permeable compounds, 
the “sink condition” was maintained by transferring the wells with cells to fresh buffer, 
HBSS-Hepes (Hank's Buffered Salt Solution containing 25 mM Hepes) at given time 
points (after 15 or 30 or 60 min). For the B-A direction, samples were only taken after 
the end of the incubation. At least three independent experiments (n=3-3) were 
performed with triplicate inserts in both directions for reference compounds. 
Permeability screening was routinely performed under iso pH condition (pH 7.4 A-7.4 
B). Before initiation of the transport studies, TEER (trans epithelial electric resistance) 
was measured (EVOM-2, WPI Inc, Sarasota, FL). Upon completion of the experiments, 
epithelial integrity was examined by toluidine blue (1%) staining. Lucifer Yellow (100 
µM) and sodium fluorescein (100 µM), markers for the paracellular pathway, were used 
to verify tight junction integrity. 
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The concentration of most test compounds in the samples was determined by 
HPLC with UV-VIS or a fluorescence detector (Merck-Hitachi LaChrom). Apparent 
permeability (Papp) was calculated with the following equation: 
 
0CA
(dQ/dt)
  Papp
x
=   
 
where dQ/dt is the rate of permeability, C0 is the initial concentration in the donor 
compartment, and A is the surface area of the filter (1.12 cm2). The efflux ratio was 
calculated, as the ratio of PappB-A to PappA-B. A ratio greater than 2.0 was accepted as 
an indicator of the efflux mechanism involvement. Verapamil HCl or quinidine (100 
µM, 30 min preincubation) were used as efflux inhibitors to confirm P-gp activity. 
For MDCK-MDR1 cells, the corrected efflux ratio was also calculated (efflux 
ratio measured in MDCK-MDR1 cells divided by the efflux ratio measured in the parent 
cells). 
 
Equilibrium dialysis measurements 
 
A 96-well equilibrium dialysis apparatus with 3.5-kDa cut-off membranes was 
used to determine the free fraction of the drugs in the plasma and brain (HTDialysis 
LLC, USA). Balb/C mouse blood and brain were obtained fresh on the day of the 
experiment. Diluted brain homogenate and plasma were spiked with the test compound 
to give a nominal final concentration of 10 µM of test substance. Dialysis against PBS 
was carried out in the 96-well equilibrium dialysis plate for 5.5 h at 37°C.  
The unbound (free) fraction (fu) for plasma and the apparent fu for brain was 
determined as the ratio of concentration in buffer to that in plasma or brain. Fu for the 
brain was calculated with correction for the dilution factor (D): 
 
( )
( )[ ]{ } Dfu
Dfu
/11apparent/1
/1
+−
=
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4. RESULTS 
 
Drug penetration model of vinblastine-treated Caco-2 (VB-Caco-2) cultures 
 
The morphological characteristics of VB-Caco-2 cultures showing compact, 
homogenous monolayers of mostly small diameter cells (Fig. 1B) appeared after 
approx. 6 passages of initiation of 10 nM vinblastine exposure, and were maintained 
throughout the whole observation period up to 200 passages with continued vinblastine 
treatment. Contrary to VB-Caco-2, Caco-2 cultures grown in normal tissue culture 
medium (no vinblastine is added) showed heterogeneous appearance of monolayers 
consisting of a mixture of patches of small cells among areas covered with relatively 
large diameter cells (Fig. 1A).  
 
 
Fig. 1. Morphology of Caco-2 (A) and VB-Caco-2 (B) monolayers. Cells seeded at a 
density of 1x 106 cells/T-75 flask and cultured for 4 days. Phase contrast images, scale 
bars: 100 µm. 
 
P-glycoprotein mRNA and protein levels in VB-Caco-2 and in Caco-2 cultures  
In VB-Caco-2 cultures the level of MDR1 mRNA was 2.2 and 4.3 times higher 
than in differentiated and undifferentiated Caco-2 cultures, respectively. Immunoblots 
(Fig. 2) show most intense expression of P-gp in VB-Caco-2 cultures. In native Caco-2 
cultures hardly any detectable level of P-gp protein was observed. 
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Fig. 2. Western blot of differentiated (D) and undifferentiated (U) Caco-2 and VB-
Caco-2 cell lysates probed for P-gp. M1 and M2: prestained molecular weight markes.  
 
Functionality of VB-Caco-2 in comparison to Caco-2: passive penetration 
The apparent permeability (PappA-B) values obtained for the passively 
penetrating reference compounds (n=12) correlated strongly (r2 = 0.9830), indicating no 
substantial difference in the passive drug penetration between the two models. 
Penetrability of the paracellularly transported Lucifer Yellow and fluorescein sodium 
was also at the same degree in the two models. 
 
Prediction of human absorption by the models 
The apparent permeabilities (PappA-B) of all reference drugs (passively 
penetrating and efflux mediated) measured in VB-Caco-2 and Caco-2 models were 
plotted against literature values for HA (human absorption). Two groups of compounds 
were clearly distinguishable. High permeability compounds with HA of higher than 
85% with an apparent permeability of at least 8.5 x 10-6 cm/s or
 
15.4 x 10-6 cm/s in the 
VB-Caco-2 or Caco-2 model, respectively; and low permeability compounds with lower 
than
 
0.6 x 10-6 cm/s PappA-B values in the VB-Caco-2 model and with lower than 1.9 x 
10-6 cm/s PappA-B in the Caco-2 model. The higher threshold Papp values with Caco-2 
for the two groups were most probably attributable to the lower P-gp sensitivity of those 
cells (Fig. 3).  
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Fig. 3. The fraction absorbed (HA%, literature data) plotted against apparent 
permeabilities (PappA-B) of reference drugs in VB-Caco-2 and Caco-2 bidirectional 
transport assay. The models differentiate two groups of drugs with slightly differing 
penetrability thresholds (dotted area: high permeability compounds; lined area: low 
permeability compounds). Bars represent S.D. 
 
P-gp functionality of VB-Caco-2 compared to Caco-2 in bidirectional transport assay 
The VB-Caco-2 assay sensitively detected all the tested P-gp substrates (efflux 
ratio > 2, n = 11). It correctly classified all low permeability P-gp substrates such as 
vinblastine, cimetidine, ranitidine, chlorothiazide, atenolol and doxorubicin, and it 
identified all high permeability P-gp substrates like verapamil, quinidine, 
dexamethasone, loperamide and labetalol. In contrast to this, the Caco-2 was unable to 
identify the high permeability reference P-gp substrates, and it also failed to recognize 
two of the low penetrability references: ranitidine and atenolol. Although other low 
permeability P-gp substrates such as vinblastine, cimetidine, chlorothiazide and 
doxorubicin were recognized by Caco-2, the notably higher efflux ratio by the VB-
Caco-2 also points to the superior sensitivity of the latter.  
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The P-gp functionality of VB-Caco-2 was monitored through a broad passage 
range between 35 and 195. During this interval, each P-gp substrate showed an efflux 
ratio of higher than 2 at each reading (Fig. 4).  
 
 
Fig. 4. Distribution of efflux ratios (mean and S.D. n = 3) of selected P-gp substrates in 
VB-Caco-2 (filled column) and in Caco-2 cultures (empty column) through a broad 
passage range. VB-Caco-2 model recognizes with efflux ratio > 2 the known P-gp 
substrates along the whole observation period. Passage numbers are indicated under 
the columns. 
 
The effect of vinblastine withdrawal on P-gp level and functionality in VB-Caco-2 
cultures 
Vinblastine withdrawal following its sustained presence in VB-Caco-2 cultures 
(through 70 passages) did not decrease the P-gp protein level or functionality. The 
protein level of differentiated cultures and bidirectional transport of selected efflux 
substrates were investigated at 10 and 33 passages after the drug withdrawal. 
 
Screening of NCEs using VB-Caco-2 and Caco-2 bidirectional transport assay 
A structurally diverse set of 91 compounds (16 structure families) synthesized in 
Richter’s preclinical research program in four different indication areas underwent 
permeability screening using both VB-Caco-2 and Caco-2 assays. The results revealed 
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that 34 out of 91 tested NCEs in VB-Caco-2 assay were P-gp substrates displaying an 
efflux ratio of > 2, while Caco-2 identified only 8 of them (Fig. 5). The Caco-2 failed to 
identify ~ 76% of compounds. For passively transported compounds (efflux ratio < 2), 
similar apparent permeability values (r2 = 0.8706) were obtained in both models in 
agreement with the observations made on reference drugs. 
 
 
Fig. 5. Apparent permeabilities (Papp A-B) (A) and distribution of efflux ratio values (B) 
of new chemical entities (NCEs) (n = 91) determined both in VB-Caco-2 and Caco-2 
bidirectional permeability assays at iso pH conditions; filled circles: efflux ratio < 2 
both in VB-Caco-2 and Caco-2 models (n = 57); open triangles: efflux ratio > 2 only in 
VB-Caco-2 model (n = 26); open square: efflux ratio > 2 both in VB-Caco-2 and Caco-
2 models (n = 8). More assumed P-gp substrates and higher accompanied efflux ratios 
appeared with the VB-Caco-2 model. The range for efflux of 0.6-2 covers compounds 
identified as subjects to passive penetration. 
 
Challenging brain penetration modelling with VB-Caco-2:    
Comparison of brain capillary endothelial cell-based and epithelial cell-based 
surrogate BBB penetration models  
 
Morphology: electron microscopy and immunohistochemistry  
The height of the brain capillary endothelial cells co-cultured with pericytes and 
astrocytes was only at about 1.5-2 µm at the perinuclear region (Fig. 6). Between the 
overlapping plasma membranes, the tight junctions, long rows of “kissing points”, can 
be seen. The surface of the endothelial cells is typically smooth but often interrupted by 
caveolae and caveolae-like invaginations. In the brain capillary endothelial cells, the 
adherens junctions and desmosomes are in structural unity with the tight junctions.  
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Fig. 6. Electron micrographs of rat BBB, VB-Caco-2 and MDCK-MDR1 cell 
cytoarchitecture. ER, endoplasmatic reticulum; ID, interdigitations; m, mitochondrion; 
N, nucleus; TJ, intercellular tight junctions; V, microvilli.  
 
Brain endothelial cells stained positively for the endothelial specific claudin-5 
but not for the epithelial type claudins (e.g., claudin-1 and -4) and they also yielded 
positive immunostaining for ZO-1 and -catenin as well (Table 1.). The brain capillary 
endothelial cells are thin and elongated, and show a swirling pattern in the monolayers. 
 
Table 1. Summary of the expression of tight junction (TJ) and adherens junction related 
proteins in rat brain capillary endothelial blood-brain barrier (BBB) and in epithelial 
models (Caco-2, VB-Caco-2, MDCK-MDR1) using immunostaining.  
 Model -catenin ZO-1 Claudin-1 Claudin-4 Claudin-5 
Rat BBB + + +/– – + 
Caco-2 + + + + – 
VB-Caco-2 + + + + – 
MDCK-MDR1 + + + + – 
+: positive staining, –: negative staining 
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Native Caco-2, VB-Caco-2 and dog kidney epithelial cultures (MDCK, MDCK-
MDR1) grow in non-overlapping monolayers and have a cuboidal shape. An obvious 
morphological difference is that the kidney epithelial cells are usually higher than the 
colon carcinoma. The apical surface of both cell types is similarly covered with 
microvilli. Between the adjacent cells, the tight junctions are relatively short (0.3-1 µm), 
and are positioned apically and well separated from other junctional structures like 
desmosomes and adherens junctions, so they could be identified as independent 
structures (Fig. 6).  
Positive staining for the integral membrane TJ proteins claudin-1 and claudin-4, 
for the cytoplasmic TJ associated ZO-1 protein and for the adherens junction protein -
catenin was demonstrated in both human colon carcinoma and dog kidney epithelial 
cells. Epithelial type cells were not stained positively for the endothelial-specific 
claudin-5 TJ protein. There was a typical cobblestone pattern in both epithelial cultures, 
but the VB-Caco-2 cultures grow in a lower density than MDCK-MDR1. 
 
P-glycoprotein expression in rat BBB EPA and in epithelial cell lines  
Western immunoblots revealed comparably intense staining of P-gp in VB-
Caco-2 and MDCK-MDR1 cultures (Fig. 7). The P-gp staining in rat brain capillary 
endothelial cells was less intense and the bands appeared at a lower molecular weight 
than in human cells. In MDCK and in native Caco-2 cell lysates, the protein level of P-
gp was under the detection limit. 
 
 
Fig. 7. Western blot analysis of lysates of rat brain capillary endothelial cells, native 
Caco-2, VB-Caco-2, MDCK-MDR1 and MDCK-parent cell lines probed for P-
glycoprotein (P-gp).  
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P-gp immunostaining revealed comparably weaker staining of P-gp for Caco-2, 
while staining differences were not obvious for the rat BBB, VB-Caco-2 and MDCK-
MDR1 cultures.  
 
Comparison of paracellular tightness of the models 
The TEER in rat BBB, native Caco-2 and VB-Caco-2 models was well above 
the critical value (150-200 Ωcm2), signifying acceptable integrity (Table 2). The 
MDCK(II) and MDCK(II)-MDR1 cultures presented a TEER that was typically below 
100 Ωcm2. The VB-Caco-2 and the MDCK-MDR1 models were the least permeable for 
fluorescein sodium (NaF), a low molecular weight marker of paracellular integrity, with 
values of 0.47 x 10-6 cm/s and 0.59 x 10-6 cm/s, respectively. The rat BBB and native 
Caco-2 models were looser, as demonstrated by the significantly higher Papp for NaF; 
(rat BBB: 2.72 x 10-6 cm/s; Caco-2: 1.34 x 10-6 cm/s; Table 2).  
 
Comparison of efflux of P-gp substrate drugs and permeability of mixed mechanism 
drugs in bidirectional assay 
Among the various models, MDCK-MDR1 and VB-Caco-2 identified the 
highest number of efflux transporter substrates, characterized with an efflux ratio higher 
than 2, which indicates more sensitive P-gp recognition of these models compared to the 
others. Accordingly, the MDCK-MDR1 (using a corrected efflux ratio) and the VB-
Caco-2 models identified five out of the seven known P-gp substrates tested (Table 2, 
bolded figures). The rat BBB model could only identify digoxin as a P-gp substrate.  
 
Correlation of in vitro and in vivo drug permeability in the models and effect of tissue 
binding and P-gp functionality 
The plasma protein- and brain tissue binding of the reference drugs were 
measured using equilibrium dialysis. The ratio of fu brain and fu plasma (fu: unbound 
fraction) values were used for the correction of Papp in vivo data (fu uncorrected Papp 
in vivo) that had previously been generated in a mouse brain distribution model. 
 By in vitro equilibrium dialysis antipyrine, caffeine, quinidine, atenolol, digoxin 
and cimetidine proved to be low plasma protein binding drugs (less than 75% binding), 
as their fu values were higher than 0.25.  
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efflux 
ratio 
corrected 
0.98 
1.00 
1.75 
1.05 
13.5 
9.79 
1.64 
50.5 
3.45 
7.56 
 
 
 
efflux 
ratio 
0.96 
0.98 
2.78 
1.16 
16.4 
17.8 
2.33 
368.5 
4.54 
53.1 
 
 
 
S.D. 
3.1 
5.6 
0.3 
4.3 
1.51 
2.67 
0.14 
0.12 
0.10 
0.09 
0.06 
 
8 
MDCK-MDR1 
PappA-B 
x10-6 cm/s 
mean 
74.6 
78.5 
15.2 
45.5 
5.19 
4.70 
0.43 
0.21 
0.78 
0.57 
0.59 
 
84 
efflux 
ratio 
0.98 
0.98 
1.59 
1.11 
1.22 
1.81 
1.42 
7.32 
1.32 
7.0 
 
 
 
SD 
2.3 
3.2 
10.6 
4.4 
3.4 
1.03 
0.20 
0.92 
0.18 
0.12 
0.16 
 
4 
MDCK 
PappA-B 
x10 -6 cm/sec 
mean 
72.6 
79.3 
25.6 
47.1 
31.8 
9.48 
0.58 
2.09 
1.04 
2.37 
0.65 
 
74 
efflux 
ratio 
0.97 
0.84 
1.60 
1.10 
4.90 
3.13 
1.95 
270.2 
3.90 
65.5 
 
 
 
S.D. 
2.5 
3.0 
7.9 
0.5 
3.6 
0.7 
0.09 
0.07 
0.56 
0.17 
0.17 
 
347 
VB-Caco-2 
PappA-B 
x10-6 cm/s 
mean 
78.1 
85.7 
40.0 
50.3 
16.3 
11.5 
0.25 
0.28 
0.96 
0.55 
0.47 
 
2012 
efflux 
ratio 
0.80 
0.94 
1.33 
1.08 
1.06 
1.46 
1.21 
10.5 
2.23 
4.72 
 
 
 
S.D. 
3.5 
1.0 
8.9 
1.4 
3.7 
1.2 
0.19 
0.95 
0.24 
0.42 
0.29 
 
184 
Caco-2 
PappA-B 
x10-6 cm/s 
mean 
82.3 
84.7 
44.6 
50.9 
40.2 
18.1 
0.83 
6.97 
1.97 
6.50 
1.34 
1024 
efflux 
ratio 
0.88 
0.92 
1.36 
1.31 
1.93 
1.40 
1.66 
0.57 
0.72 
2.46 
 
 
S.D. 
1.5 
1.9 
2.2 
1.3 
0.04 
2.30 
0.20 
0.97 
0.73 
0.27 
0.03 
125 
Rat BBB 
PappA-B 
x10-6 cm/s 
mean 
51.8 
64.9 
23.4 
33.6 
6.28 
15.6 
1.36 
2.42 
3.86 
1.25 
2.72 
TEER (cm2), mean ±S.D. 
548 
Major efflux 
transporters 
 
 
P-gp 
 
P-gp 
P-gp 
P-gp 
P-gp, MRP2 
P-gp, BCRP 
P-gp 
 
 
 
Primary 
transport 
mech. 
PT 
PT 
PT/E 
PT 
PT/E 
PT/E 
PP/E 
E 
E 
E 
PP 
 
 
Table 2. Permeability (Papp) and efflux ratio values of drugs and Trans Epithelial Electric Resistance (TEER, cm2) measured in the 
rat blood-brain barrier (BBB), native Caco-2, VB-Caco-2, MDCK and MDCK-MDR1 models. 
Compound 
Antipyrine 
Caffeine 
Verapamil 
Indomethacin 
Quinidine 
Loperamide 
Atenolol 
Vinblastine 
Cimetidine 
Digoxin 
Fluorescein-Na 
 
 
Compounds were measured at 10 µM, except for sodium fluorescein (100 µM). Bold numbers indicate efflux mechanism (efflux ratio 
higher than 2). Results for Caco-2, VB-Caco-2, MDCK and MDCK-MDR1 are added as their mean and inter assay S.D. values obtained 
in at least 3 independent experiments with 3 parallels of identical treatments within assays. For rat BBB model a single experiment 
(with triplicate inserts) was performed. PT: passive transcellular; PP: passive paracellular; E: Efflux 
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Verapamil, indomethacin, loperamide and vinblastine appeared to be moderate/high 
plasma protein binding drugs (binding equal or higher than 90%), with fu of less than or 
equal to 0.1.  
 Taking the fu brain values (unbound fraction in brain tissue) determined also 
with equilibrium dialysis, the fu brain to fu plasma ratios appeared to be close to 1 for 
caffeine, antipyrine, atenolol, cimetidine and digoxin. The brain tissue binding of 
verapamil, quinidine and loperamide was slightly higher than their plasma protein 
binding; therefore, correction with fu brain to fu plasma ratio resulted in a lower in vivo 
Papp values than the uncorrected in vivo Papp (2-3-fold shift). The most dramatic shifts 
in fu corrected Papp in vivo appeared for indomethacin (4.9-fold increase) and 
vinblastine (8-fold decrease). Indomethacin has high plasma protein binding (fu plasma: 
0.017) with relative lower brain tissue binding (fu brain: 0.082), but vinblastine has high 
brain tissue binding (fu brain: 0.013) with relative lower plasma protein (fu plasma: 
0.105); therefore, the fu ratios are significantly deviate from one and markedly change 
the value of the Papp in vivo. 
  
Table 3. The r2 values of correlations between in vitro permeability (Papp) determined 
in the different cell-based models of drug permeability and the fu brain/fu plasma ratio 
corrected or the tissue binding uncorrected in vivo Papp values. BBB, triple co-culture 
blood-brain barrier model. 
r2 value Permeability 
model 
in vitro Papp versus fu 
brain / fu plasma ratio 
corrected Papp in vivo 
in vitro Papp versus 
tissue binding un-
corrected Papp in vivo 
Rat BBB 0.7989 0.4391 
Caco-2 0.6053 0.4430 
VB-Caco-2 0.7206 0.3851 
MDCK 0.6809 0.4217 
MDCK-MDR1 0.7782 0.3352 
 
 The fu corrected or the fu un-corrected Papp in vivo data (calculated on the basis 
of total drug concentrations) of the reference drugs was plotted against the in vitro 
permeability data determined in rat BBB and in native Caco-2, VB-Caco-2, MDCK and 
MDCK-MDR1 models. When tissue binding uncorrected Papp in vivo data was used, 
no substantial correlation was observed in any of the models (r2< 0.45) for the tested 
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reference compounds (Table 3). On the contrary, when the in vitro permeabilities were 
plotted against tissue binding corrected Papp in vivo data, a correlation was obtained 
(r2=0.7989-0.6053); the goodness of fit was similar in the models (Table 3). Those 
compounds with a significant deviation of the fu brain to fu plasma ratio from 1, such as 
indomethacin (fu brain to plasma 4.9) and vinblastine (fu brain to plasma 0.12), are 
outliers if uncorrected data is plotted, whereas corrected values substantially improve 
the power of correlation.  
 The results also show the positive effect of P-gp functionality in the models on 
the goodness of in vitro – in vivo correlations. The high and low P-gp functionality 
counterparts VB-Caco-2 versus Caco-2 and MDCK-MDR1 versus MDCK models 
clearly point to the trend of better predictivity (higher r2 value) of the high P-gp 
functionality model in comparison with its low P-gp counterpart (Table 3). 
 
Comparison of high P-gp activity models: VB-Caco-2 versus MDCK-MDR1  
In vitro permeability (Papp) was determined for a large set of chemically diverse 
drugs (n = 59) and NCEs (n = 62) in VB-Caco-2 and the well accepted surrogate BBB 
model of MDCK-MDR1. A strong correlation was found in terms of the permeability 
(Fig. 8) in the models.  
 
 
 
Fig. 8. Correlation between permeability (Papp) data of reference drugs (n=59) and 
NCEs (n=62) determined in VB-Caco-2 and in MDCK-MDR1 models. 
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5. DISCUSSION 
 
A high P-gp expressing VB-Caco-2 culture was developed via vinblastine 
treatment of Caco-2 cells and characterized in comparison to Caco-2 culture. The VB-
Caco-2 cells show compact, homogenous monolayers, similar passive permeability as 
Caco-2 model in bidirectional transport assay, but the VB-Caco-2 model is more 
sensitive in identifying P-gp substrates and could reliably be used with steady P-gp 
features through long passages. It is suitable for the prediction of drug absorption and 
examination of P-gp mediated interactions in bidirectional transport assay. We showed 
that omitting vinblastine from established VB-Caco-2 cultures did not affect either the 
protein level or the functionality of P-gp, which confirms the selectional mechanism of 
vinblastine.  
Furthermore, comparison of epithelial cell-based models, including the VB-
Caco-2 model as possible surrogate BBB models, was performed with the primary brain 
capillary endothelial BBB model (EPA). Despite the different morphology, epithelial-
based models provide integrity that is very much on a par with that of rat BBB model, 
and the models show similar passive transcellular permeability, which makes them 
highly comparable to the rat BBB model. While the P-gp functionality of the rat BBB 
model was low, the VB-Caco-2 and the MDCK-MDR1 models identified the highest 
number of P-gp substrate drugs. Significant correlation was obtained between the in 
vitro and in vivo brain permeability using all models if the in vivo values were corrected 
with the ratio of free fraction of brain and plasma. A strong correlation was found in 
terms of the permeability in the VB-Caco-2 and the well accepted surrogate BBB model 
of MDCK-MDR1 for a large set of chemically diverse drugs and NCEs.  
In conclusion, the VB-Caco-2 culture provides a reliable tool for the penetration 
screening of drugs and NCEs. The VB-Caco-2 model with steady P-gp features is 
suitable for the identification of P-gp substrates with drug-drug interaction potential. 
The VB-Caco-2 model may provide an alternative of the widely recognized surrogate 
BBB model MDCK-MDR1 and the more labour-intense and expensive brain capillary 
endothelial-based BBB model for fast screening of drug candidates for brain 
permeability. 
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